Apr 14, 2023 8:30am EDT RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
Apr 11, 2023 8:30am EDT RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
Mar 30, 2023 12:20pm EDT RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Mar 30, 2023 8:30am EDT RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
Mar 08, 2023 8:30am EST RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGem™ as a Treatment Option for Locally Advanced Pancreatic Cancer
Mar 02, 2023 8:30am EST RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
Jan 25, 2023 8:30am EST RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
Jan 18, 2023 8:30am EST RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
Jan 05, 2023 8:30am EST RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
